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A. Cappelli, R.A. Trovato and D. BeneventoVascular and Endovascular Surgery, University of Siena, Viale Bracci 1, I-53100 Siena, ItalyPurpose. This study aims to review the incidence of in-stent restenosis (ISR), the factors which determine restenosis, and to
evaluate the use of various endovascular techniques for the management of ISR following carotid artery stenting (CAS).
Methods. Four hundred and seven patients (334 men, mean age 63 years, range 46–86, median 65 years) were treated with
CAS between December 2000 and March 2004. Three hundred and seventy-two (89%) patients had at least one ultrasound
evaluation performed 6 months after procedure (range 6–40). Recurrent stenosis O80% detected with duplex ultrasound
scans were further evaluated by angiography and treated with repeat endovascular procedure.
Results. CAS was performed successfully in all cases with a Carotid WallStent (Boston Scientific) using a cerebral
protection device (filter). Perioperative complications included four (0.9%) minor and two (0.4%) major strokes these latter
two patients died at 5 and 12 days after the operation. No other deaths occurred. A total of 15 carotid arteries (3.6%) in 14
patients had ISR. All ISR were treated with a repeat endovascular procedure: three balloon angioplasty alone, eight
angioplasty and secondary stenting, four angioplasty with cutting balloon. Postsurgical restenosis was confirmed to be the
only predictive factor for the development of in-stent restenosis (OR 14.5, 95% CI 2.3–113.4, pZ0.005). Endovascular
treatment of ISR achieved technical success without periprocedurale complications and the absence of significant restenosis
over a median follow up time of 12.4 months (range 3.5–30.7).
Conclusion. Our experience with a large cohort of CAS showed an encouragingly low incidence of ISR (3.6%) and
successful treatment by repeat endovascular intervention. We recommend attempting all endovascular possibilities before
performing stent removal.Keywords: Carotid disease; Carotid artery stenting; In-stent restenosis; Cutting balloon angioplasty.Carotid angioplasty and stenting (CAS) is being used
widely to treat severe carotid obstructive disease, and it
is now accepted as a less invasive technique that
provides an alternative for some patients, particularly
thosewith significant comorbidities.1–5 Theprocedure is
also an attractive therapeutic option for patients with
local anatomical factors that make carotid endarterect-
omy (CEA) difficult or riskier, i.e. restenosis after earlier
surgery, ‘hostile neck’ after radical surgery and/or
radiation therapy, distal internal carotid artery (ICA)
lesions and carotid dissections.6,7 Although early results
from several centres have been encouraging, concerns
remain regarding long-term durability of CAS. In-stent
restenosis (ISR) in other vascular beds ranges from 1 to
50% inpublished reports8 and is themore frequent long-
term complication of CAS.9–12
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0601+ 07 $35.00/0 q 2005 Elsevier Ltd. All rights reserthe incidence of ISR after CAS.10 In the first 195 CAS
procedures, we observed 10 cases of ISR (5.2%). We
also identified clinical factors, which determine ISR.
The multivariate analysis supported the multifactorial
origin of this complication. Our results showed that
postsurgical restenosis was the only predictive factor
for the development of ISR. Now our experience with
CAS procedures has grown significantly, passing from
195 to 418 cases. This new study intends to review the
factors determining restenosis, and to evaluate the use
of various endovascular techniques for the manage-
ment of ISR (repeat angioplasty, angioplasty and
secondary stenting, angioplasty with cutting balloon).Material and MethodsStudy design and patient sample
A retrospective study was conducted of patientsEur J Vasc Endovasc Surg 29, 601–607 (2005)
doi:10.1016/j.ejvs.2005.01.033, available online at http://www.sciencedirect.com onved.
C. Setacci et al.602undergoing CAS for significant de novo or recurrent
carotid artery occlusive disease between December
2000 and March 2004. Clinical, laboratory, diagnostic,
and operative reports, as well as the hospital and
postoperative course of each patient, were stored in a
computerized database. Interrogation of the database
identified 407 consecutive patients (334men; range 46–
86, median age 65 years) who underwent CAS, which
represented 29.5% of the 1416 carotid procedures. The
aetiology of the 418 lesions (11 bilateral treated in
staged procedures) was de novo stenosis in 230 (55.1%)
and postsurgical restenosis in 188 (44.9%). The
indications for primary stenting were: significant
medical comorbid conditions, such as coronary artery
disease requiring angioplasty or bypass grafting that
had not or could not be revascularized, history of
congestive heart failure, current ejection fraction 30%
or less, steroid-dependent chronic obstructive pul-
monary disease, or measured 1-s forced expiratory
volume 30% or less; primary lesions anatomically
inaccessible at surgery; previous ipsilateral cervical
radiation therapy. A large number of patients were
symptomatic (301, 72.8%). The majority of the pro-
cedures (411, 98.4%) were elective, and seven (1.6%)
were urgent. All procedures were performed using a
cerebral protection device (FilterWire EX—Boston
Scientific in 386 cases, 92.1%). Plaque echogenicity as
assessed by B-mode ultrasound (3500 HDI Philips
Medical System/ATL S.p.A.—Bothell, USA) has been
found to reliably predict the content of soft tissue and
the amount of calcification in carotid plaques. Plaque
morphology in terms of echogenicity, defined as
reflection of the emitted ultrasound signal, was
assessed in a modified version of the classification
proposed by Gray-Weale et al. and graded from 1 to 4
as echolucent, predominantly echolucent, predomi-
nantly echogenic, or echogenic.Carotid stent protocol
Our carotid stent protocol is described in Journal of
Endovascular Therapy: vol. 10, No. 6, pp. 1031–1038.Follow-up protocol and criteria for restenosis assessment
All patients were followed at the hospital’s outpatient
clinic at 1, 3, 6 and 12 months after the procedure and
every 6 months thereafter. During these routine
postoperative visits, the surgeon examined each
patient, and a carotid duplex scan was performed. If
any change in neurological status was found, either a
brain CT or MRI was performed. Exact information
about clinical events was obtained in all patients. TheEur J Vasc Endovasc Surg Vol 29, June 2005diagnosis and quantification of restenosis was per-
formed noninvasively using color-coded duplex ultra-
sonography; in the majority of cases, an intracranial
Doppler flow study was also performed. Velocity
criteria used to identify individual categories of
restenosis are based on a modification of the Univer-
sity of Washington criteria (according to parameters of
Lal et al.12): peak systolic velocity (PSV) less than
130 cm/s, 0–39%; PSV 130–210 cm/s, 40–59%; PSV
210–300 cm/s with end-diastolic velocity less than
120 cm/s, 60–79%; PSV greater than 300 cm/s and
end-diastolic velocity greater than 120 cm/s, or
internal carotid to common carotid artery systolic
velocity ratio greater than 3.2, 80–99%. Clinically
significant recurrent stenosis was defined as any ISR
of 80% or greater.Statistical analysis
Data sets were analyzed using univariate methods
with the goal of determining the risk factors correlated
to the development of ISR. Variables that were
believed to have an impact on ISR in the carotid
arteries included age, sex, smoking, chronic obstruc-
tive pulmonary disease, hypertension, diabetes melli-
tus, hypercholesterolemia (O200 mg/ml), unstable
angina, stable coronary artery disease, chronic heart
failure, abdominal aortic aneurysm, peripheral arterial
disease, malignancy or autoimmune disease, ISR in
other vascular districts, symptomatic stenosis, post-
surgical carotid restenosis, CCA intimal thickness,
carotid plaque type, long-term pre-CAS antiplatelet
therapy, creatinine level O1.3 g/l, baseline vessel
diameter, vessel diameter after stenting, postoperative
fever, and postoperative white blood cell count (Table
1). The StatXact statistical package (Cytel Software
Corporation, Cambridge, MA, USA) was used. A two-
tailed permutation test was performed to test differ-
ences among continuous variables. The Fisher exact
test was used to test categorical variables. Cox
proportional analysis was used to determine indepen-
dent predictors of in-stent restenosis; a probability of
%0.10 was used to enter variables into the Cox model
in a forward-stepwise manner. A probability %0.15
was used to remove variables from the model.
Independent predictor variables that contributed to
the final multivariate model were considered signifi-
cant risk factors for restenosis if p%0.05. Continuous
data are presented as the meanGSD. The nonpara-
metric Wilcoxon rank sum test was used for group
comparisons, while nominal data were analyzed with
the chi-square test; p!0.05 indicated a significant
difference. To evaluate the fate of the CAS procedure,
Table 1. Results of the univariate analysis
All patients (nZ407) With restenosis (nZ14) Without restenosis (nZ393) p
Age, years 65.2 (56.3–74.7) 61.3 (50.3–72.7) 66.9 (56.0–73.3) 0.73
Men 334 (82%) 12 (85%) 322 (81.9%) 0.43
Smokers 102 (25.6%) 7 (50%) 95 (24.2%) 0.13
COPD 110 (27%) 4 (28%) 106 (26.9%) 1.0
Hypertension 370 (90.9%) 14 (100%) 356 (90.6%) 1.0
Diabetes mellitus 130 (31.9%) 6 (42%) 124 (31.5%) 0.6
Hypercholesterolemia 183 (44.9%) 8 (57%) 175 (44.5%) 0.82
Coronary artery disease 154 (37.8%) 3 (21%) 151 (38.4%) 0.54
Unstable angina 20 (4.9%) 2 (14%) 18 (4.6%) 1.0
Abdominal aortic aneurysm 71 (17.4%) 5 (35%) 66 (16.7%) 0.052
Peripheral arterial disease 109 (26.7%) 7 (50%) 102 (25.9%) 0.41
Malignancy or autoimmune disease 73 (17.9%) 5 (35%) 68 (17.3%) 0.43
Symptomatic stenosis 301 (73.9%) 5 (35%) 296 (75.5%) 0.15
Postsurgical carotid restenosis 219 (46%) 14 (100%) 174 (44.3%) 0.005
CCA intimal tickness, mm 0.55 (0.41–0.67) 0.57 (0.38–0.67) 0.53 (0.40–0.65) 0.33
Plaque echolucent 24 (5.9%) 4 (28%) 20 (5.1%) 0.9
Plaque predominantly echolucent 11 (28.1%) 9 (64%) 105 (32.8%) 0.16
Plaque predominantly echogenic 130 (31.9%) 1 (7%) 129 (26.7%) 0.6
Plaque echogenic 139 (34.1%) 0 (0%) 139 (35.4%) 0.56
Pre-CAS antiplatelet therapy 341 (83.7%) 14 (100%) 327 (83.2%) 0.4
CreatinineO1.3 g/l 48 (11.7%) 4 (28.5%) 44 (11.2%) 0.74
Diameter pre/post CAS, % 135 (118–166) 144 (130–160) 134 (118–165) 0.15
Postoperative fever 131 (32.2%) 8 (64.3%) 122 (31%) 0.07
Infection (lung, urinary, local) 41 (10%) 1 (7.1%) 40 (10.2%) 0.41
ISR After CAS 603Kaplan–Meier survival analyses were generated for
overall survival, freedom from neurological events,
and freedom from ISR.Results
In all cases, a Carotid WallStent Monorail (Boston
Scientific) was successfully deployed, with previous
placement of a FilterWire EX (Boston Scientific) to
prevent cerebral emboli. Overall perioperative com-
plications included four (0.9%) minor strokes, and two
(0.6%) major strokes (one intracranial haemorrhage
and one hemispheric stroke); these latter two patients
died at 5 and 12 days after the operation. No other
deaths occurred. One of the minor stroke patients
underwent successful urgent surgical treatment for in-
stent thrombosis. The median duration of surveillance
for all 405 survivors was 21 months (absolute range 0–
39.1). Five other deaths, all nonprocedure-related,
occurred at 42, 44, 60, 111 and 126 days, yielding an
overall mortality rate of 1.7% (7/407) for the entire
series. The Kaplan–Meier survival analysis (Fig. 1) for
the entire series yielded a 97.6% survival rate (95% CI
93.2–98.9%).
During follow-up, nine additional neurological
events (two major strokes and seven transient
ischemic attacks) were observed; five events were
ipsilateral to the treatment site. None of the neuro-
logical events occurred in patients with restenosis. The
freedom from neurological events, minor stroke andmajor stroke, (Fig. 2) was 90.2% at 39 months. Fourteen
patients, for a total of 15 carotid axes (15/418, 3.6%)
had ISR, in one case the restenosis was bilateral.
Double (tandem) ISR was found in two cases. The
segments affected by restenosis were three proximal
ends (common carotid artery), six distal ends (internal
carotid artery) and six middle segments of the stent.
The ISR in two cases were moderate (50–79%) and in
11 severe (O80%). Five patients were symptomatic
and nine asymptomatic. In the two cases of moderate
ISR, re-intervention was recommended because of the
presence of accompanying contra-lateral occlusion.
The cumulative rate of freedom from restenosis was
93.1% at 39 months (Fig. 3).
All ISRs were treated with a further endovascular
procedure: three repeat balloon angioplasty (rBA);
eight repeat angioplasty and secondary stenting
(rCAS); four angioplasty with cutting balloon (CB).
All the procedures were performed using a cerebral
protection device (FilterWire EX—Boston Scientific).
The first 10 cases of ISR were treated with rBA,
utilising conventional balloon. A residual stenosis O
30% required a secondary stenting in seven cases. In
the last five cases of ISR, the procedures were
successfully performed with a CB using low inflation
pressures. Only in one case a residual stenosis
required an additional stent (Fig. 4). No procedure-
related complication occurred within 30 days after any
treatment for ISR.
Each patient was strictly followed up with US
scanning at 1, 3, 6, 9, 12 months and every 6 monthsEur J Vasc Endovasc Surg Vol 29, June 2005
Fig. 1. Cumulative survival analysis.
C. Setacci et al.604thereafter. Table 2 shows the mean follow-up interval,
the % of restenosis—calculated by geometric criteria
(comparison of the least transverse diameter at the
stenosis with the reference distal internal carotid
artery), the median peak systolic velocity (PSV) inFig. 2. Cumulative freedom
Eur J Vasc Endovasc Surg Vol 29, June 2005the internal carotid artery (ICA), and the mean internal
carotid to common carotid PSV ratio for each group of
ISR treated with rBA or rCAS or CB. No significant
statistical difference was noted between the three
groups for each parameter of restenosis (pO0.1).from neurological events.
Fig. 3. Cumulative freedom from in-stent restenosis at 39 months.
ISR After CAS 605All patients remained asymptomatic and without
recurrent restenosis greater than 30% over a median
follow-up of 12.4 months (range 3.5–30.7). The multi-
variate analysis of factors determining restenosis
confirm the multifactorial origin of the condition as
already reported in our previous study. Postsurgical
carotid restenosis in association with postoperative
fever (OR 5.3), the need for carotid predilation (OR
3.9), or concomitant malignancy or autoimmune
disease (OR 3.4) are key predictors for development
of ISR (Table 3).Fig. 4. Management of carotiDiscussion
The long-term outcome after CEA has been well-
documented in several studies;13 however, despite
several thousand CAS procedures reported in the
literature, the long-term incidence of ISR remains ill-
defined. In addition, the high incidence of recurrent
stenosis after coronary stenting14 and femoro-iliac
angioplasty with stenting15 has prompted several
clinicians to question the durability of the CAS
procedure. In-stent recurrent stenosis after carotidd in-stent restenosis (ISR).
Eur J Vasc Endovasc Surg Vol 29, June 2005
Table 2. Characteristics of treated ISR at ultrasound follow-up
ISR treatment n Follow up mean
interval (months)
% Restenosis
(geometric criteria)
ICA PSV (cm/s) ICA/CCA PSV ratio
rBA 3 15.4 (8–30) 17G8 105G15 1.8G0.1
rCAS 8 16 (9–28) 22G7 122G13 1.7G0.2
CB 4 6.2 (3.5–10) 14G5 95G11 1.4G0.1
ISR, in-stent restenosis; rBA, repeat balloon angioplasty; rCAS, repeat carotid artery stenting; CB, cutting balloon; PSV, peak systolic velocity;
ICA, internal carotid artery; CCA, common carotid artery.
C. Setacci et al.606artery stenting has been reported as a relatively
infrequent complication by some authors, with an
incidence of 3.5–4.9% published.1–3 On the contrary
other authors stated that carotid ISR is common and
unpredictable, reporting a prevalence of restenosis O
21% at 18 months.11,16
Our experience with a large cohort of patients (418
CAS followed for a median 21 months) showed an
encouragingly low incidence of ISR (3.6%). The
multivariate analysis of factors determining restenosis
confirms the results previously reported from our
initial experience: patients who develop restenosis
after surgical endarterectomy are also prone to
develop restenosis after CAS. Surgical removal of a
stent has not been required in this series; however,
some authors suggest that standard CEAwith removal
of the stent appear to be feasible.17,18 We preferred to
avoid surgical stent removal in all cases. The patients
who undergo CAS are generally at high risk for
surgical intervention, particularly if that have post-
surgical restenosis. The surgical exposure of the
carotid artery in patients, who have undergone CAS,
can be particularly complicated because of scarring
and the need to access the artery proximal and distal to
the stent. Our study demonstrates that ISR can be
managed successfully with further endovascular
procedures. A repeat angioplasty with a conventional
or cutting balloon was always the first solution
proposed. When we observed a suboptimal response
to dilatation with a residual stenosis O30%, a further
stent was placed to obtain a satisfactory result.
Although in the early phase of our experience withTable 3. Results of the multivariate analysis
Model term Odds ratio
Surgical carotid restenosis 1.32
Post-op fever 1.14
Need of predilatation 1.17
Malignancy/autoimmune
disease
1.20
Surgical carotid restenosis
And Post-op fever 5.36
And Need of predilatation 3.89
And Malignancy/autoimmune
disease
3.45
Eur J Vasc Endovasc Surg Vol 29, June 2005the management of carotid ISR we often had to place a
second stent, and although at the moment in literature
there are not sufficient data to evaluate rBA vs rCAS,
we think that is better to avoid an additional stent. In
our series, all carotid ISR treated with rCAS at US
follow-up showed a kink or bend in the distal ICA and
a major hyperplastic reaction at the distal end of the
second stent. The application of another stent distally
to first one, can change the anatomy of the ICA,
resulting in an even sharper bend at the end of the new
stent. Consequently, one edge of the stent is projecting
into the vessel lumen, whereas the other edge touches
the vessel wall and can stimulate a hyperplasia
reaction.19
In our experience, the requirement for additional
stent implantation was significantly lower using a
cutting balloon (1/5, 20%), compared with a conven-
tional balloon (7/10, 70%). The microsurgical blades of
the CB cut directly into the stenotic lesion and disrupt
the fibroelastic continuity of the ring of myointimal
hyperplasia. These incisions facilitate the maximum
extrusion of the neointimal plaque, separated into
three or four quadrants. Consequently, the recoil
tension is reduced compared to the diffuse hoop stress
produced by conventional angioplasty. Angioplasty
with CB for the treatment of coronary ISR was
demonstrated to have some procedural advantages,
such as the use of fewer balloons, less requirement for
additional stents, and a lower incidence of balloon
slippage.20 Our initial practice with CB to treat carotid
ISR is encouraging both in term of high procedural
success rates, significantly lower need for95% CI for odds ratio p-value
Lower Upper Two-sided
0.16 2.55 0.0017
0.65 2.97 0.041
0.58 1. 86 0.039
0.61 2.05 0.0022
3.25 18.67 0.0266
2.28 9.64 0.0310
2.13 14.43 0.0186
ISR After CAS 607supplementary stenting, low peri-procedural compli-
cation rates, and low in-stent restenosis.
This study was a retrospective analysis of prospec-
tively gathered data in the context of a nonrandomized
design. The small number of observations of ISR
represents a potential limitation and consequently
restricts the information provided by the study. The
small number of observations influenced the wide
confidence intervals associated with the odd ratios
obtained from Cox regression analysis.
Although the current approach to the treatment of
ISR is relatively simple and safe with an endovascular
procedure, newer, more aggressive approaches are
currently at the investigational level and include
intravascular brachytherapy, antiproliferative therapy
with drug-coated stents used in other vascular beds,
and biodegradable stents. In the absence of evidence
for these techniques, we think that the best manage-
ment of ISR is by repeat endovascular angioplasty, and
we recommend attempting all intraluminal possibili-
ties (rBA, rCAS or CB) before performing stent
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